These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 1165625)

  • 1. [Hypodysfibrinogenemia: fibrinogen giessen II (author's transl)].
    Krause WH; Huth K; Heene DL; Lasch HG
    Klin Wochenschr; 1975 Aug; 53(16):781-2. PubMed ID: 1165625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Dysfibrinogenemia. A new case: dysfibrinogenemia Giessen III (author's transl)].
    Matthias FR; Krause WH; Ganssert S; Mueller K; Lasch HG
    Klin Wochenschr; 1977 Jun; 55(11):539-43. PubMed ID: 881774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acquired dysfibrinogenemia secondary to mithramycin toxicity.
    Ashby MA; Lazarchick J
    Am J Med Sci; 1986 Jul; 292(1):53-5. PubMed ID: 2940861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibrinogen date: congenital hypodysfibrinogenemia associated with decreased binding of tissue-plasminogen activator.
    Ieko M; Sawada K; Sakurama S; Yamagishi I; Isogawa S; Nakagawa S; Satoh M; Yasukouchi T; Matsuda M
    Am J Hematol; 1991 Aug; 37(4):228-33. PubMed ID: 1830454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subunits and susceptibility of fibrins formed from bovine fibrinogen by arvin, reptilase, thrombin and staphylothrombin.
    Zajdel M; Wegrzynowicz Z; Sawecka J; Kopeć M
    Thromb Res; 1975 Apr; 6(4):337-44. PubMed ID: 1169826
    [No Abstract]   [Full Text] [Related]  

  • 6. Fibrinogen Houston: a dysfibrinogen exhibiting defective fibrin monomer aggregation and alpha-chain cross-linkages.
    Weinger RS; Rudy C; Moake JL; Conlon CL; Cimo PL
    Am J Hematol; 1980; 9(3):237-48. PubMed ID: 6165239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two novel mutations in the fibrinogen γ nodule.
    Kotlín R; Pastva O; Stikarová J; Hlaváčková A; Suttnar J; Chrastinová L; Riedel T; Salaj P; Dyr JE
    Thromb Res; 2014 Oct; 134(4):901-8. PubMed ID: 25074738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dysregulated coagulation associated with hypofibrinogenaemia and plasma hypercoagulability: implications for identifying coagulopathic mechanisms in humans.
    Marchi R; Walton BL; McGary CS; Lin FC; Ma AD; Pawlinski R; Mackman N; Campbell RA; Di Paola J; Wolberg AS
    Thromb Haemost; 2012 Sep; 108(3):516-26. PubMed ID: 22836883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibrinogen Bethesda: a congenital dysfibrinogenemia with delayed fibrinopeptide release.
    Gralnick HR; Givelber HM; Shainoff JR; Finlayson JS
    J Clin Invest; 1971 Sep; 50(9):1819-30. PubMed ID: 5564389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibrinogen Philadelphia. A hereditary hypodysfibrinogenemia characterized by fibrinogen hypercatabolism.
    Martinez J; Holburn RR; Shapiro SS; Erslev AJ
    J Clin Invest; 1974 Feb; 53(2):600-11. PubMed ID: 11344575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibrinogen Marburg a new genetic variant of fibrinogen.
    Fuchs G; Egbring R; Havemann K
    Blut; 1977 Feb; 34(2):107-18. PubMed ID: 836966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibrinogen Cleveland II. An abnormal fibrinogen with defective release of fibrinopeptide A.
    Crum ED; Shainoff JR; Graham RC; Ratnoff OD
    J Clin Invest; 1974 May; 53(5):1308-19. PubMed ID: 4856883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibrinogen Stony Brook II: partial characterization of a heterozygously transmitted peptide A anomaly.
    Galanakis DK; Hultin M
    Blood Coagul Fibrinolysis; 1990 Oct; 1(4-5):567-70. PubMed ID: 2133235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preferential degradation of soluble fibrin monomers in streptokinase-activated plasma.
    Konttinen YP; Lalla ML; Turunen O
    Thromb Diath Haemorrh; 1973 Nov; 30(2):403-13. PubMed ID: 4543990
    [No Abstract]   [Full Text] [Related]  

  • 15. Fibrinogen Baltimore II: congenital hypodysfibrinogenemia with delayed release of fibrinopeptide B and decreased rate of fibrinogen synthesis.
    Ebert RF; Bell WR
    Proc Natl Acad Sci U S A; 1983 Dec; 80(23):7318-22. PubMed ID: 6580646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Increased thrombin time in a patient with multiple myeloma].
    Bohler A; Redondo M; Lämmle B
    Ther Umsch; 1999 Sep; 56(9):491-4. PubMed ID: 10517116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dysfibrinogenaemia associated with a defect in the aggregation of the fibrin monomers (Almeria I fibrinogen). A preliminary study.
    Vila V; Regañon E; Fernandez-Pavon A; Aznar J
    Scand J Haematol; 1984 Nov; 33(5):460-5. PubMed ID: 6515329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dysfibrinogenemia associated with liver disease.
    Palascak JE; Martinez J
    J Clin Invest; 1977 Jul; 60(1):89-95. PubMed ID: 874092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel natural mutation AαPhe98Ile in the fibrinogen coiled-coil affects fibrinogen function.
    Riedelová-Reicheltová Z; Kotlín R; Suttnar J; Geierová V; Riedel T; Májek P; Dyr JE
    Thromb Haemost; 2014 Jan; 111(1):79-87. PubMed ID: 24108601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in the function and secretion of congenital aberrant fibrinogenemia between heterozygous γD320G (Okayama II) and γΔN319-ΔD320 (Otsu I).
    Mukai S; Ikeda M; Takezawa Y; Sugano M; Honda T; Okumura N
    Thromb Res; 2015 Dec; 136(6):1318-24. PubMed ID: 26573395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.